Lokinal Intim (Spray) Instructions for Use
Marketing Authorization Holder
Kirov Pharmaceutical Factory, JSC (Russia)
ATC Code
D06BB (Antiviral drugs)
Active Substance
Ammonium glycyrrhizate (Ph.Eur. European Pharmacopoeia)
Dosage Form
| Lokinal Intim | Spray for topical and external use 0.1%: 15 ml or 60 ml bottle. |
Dosage Form, Packaging, and Composition
Spray for topical and external use in the form of a transparent solution from light yellow to light brown in color, with a characteristic odor.
| 1 ml | |
| Ammonium glycyrrhizate (glycyram) | 1 mg |
Excipients: malic acid – 30 mg, fumaric acid – 20 mg, ascorbic acid – 3 mg, folic acid – 0.8 mg, propylene glycol – 500 mg, Tween-80 (polysorbate-80) – 9 mg, purified water – up to 1 ml.
15 ml – bottles (1) – cardboard packs.
60 ml – bottles (1) – cardboard packs.
Clinical-Pharmacological Group
Antiviral drug for external and topical use
Pharmacotherapeutic Group
Antiviral and immunostimulating agent
Pharmacological Action
Ammonium glycyrrhizate has a complex therapeutic effect ( antiviral, anti-inflammatory, immunostimulating, antipruritic, and regenerating).
Ammonium glycyrrhizate has an antiviral effect on various types of DNA and RNA viruses in vitro and in vivo ( Varicella Zoster, herpes simplex virus types I and II, cytomegalovirus, various types of human papillomavirus, including oncogenic ones).
Ammonium glycyrrhizate interrupts virus replication at early stages, causes the virion to exit the capsid, thereby preventing its penetration into cells.
It inactivates the specified viruses at concentrations that are non-toxic to normally functioning cells.
Mutant virus strains resistant to acyclovir and iodouridine are highly sensitive to the drug, as are non-mutant strains.
Ammonium glycyrrhizate has anti-inflammatory activity, which is combined with a stimulating effect on humoral and cellular immunity.
It significantly inhibits the release of kinins and the synthesis of prostaglandins by connective tissue cells in the inflammation zone.
The immunostimulating effect is manifested by an increase in the number and activity of T-lymphocytes, a decrease in the concentration of immunoglobulin G, and an increase in the concentration of immunoglobulins A and M.
It induces the production of its own interferons.
The regenerating action is due to the improvement of skin and mucous membrane repair.
Pharmacokinetics
With topical and external application, Ammonium glycyrrhizate is deposited in the lesions. Systemic absorption occurs slowly. The drug is detected in the blood in trace amounts.
Indications
Viral infection caused by human papillomavirus, including asymptomatic excretion of high oncogenic risk human papillomavirus as part of combined and complex therapy; viral infection caused by herpes simplex virus types I and II as part of complex therapy; viral infection caused by Varicella Zoster virus (herpes zoster) as part of complex therapy; viral infection caused by cytomegalovirus as part of complex therapy; prevention of recurrences of viral infections caused by herpes simplex virus types I and II, Varicella Zoster virus, human papillomavirus, cytomegalovirus; prevention and treatment of anogenital warts and cervical pathologies caused by human papillomavirus, cytomegalovirus; prevention and treatment of conditions accompanied by decreased local immunity, including nonspecific vulvovaginitis, candidal vulvovaginitis and bacterial vaginosis, as part of complex therapy; for symptoms of discomfort in the genital area, accompanied by itching, burning and dryness of the mucous membranes, including after sexual intercourse; for symptoms of discomfort in the genital area, accompanied by itching, burning and dryness of the mucous membranes in ovarian insufficiency.
ICD codes
| ICD-10 code | Indication |
| A60 | Anogenital herpesviral infection [herpes simplex] |
| A63.0 | Anogenital [venereal] warts (condyloma acuminatum) |
| B00 | Herpesviral [herpes simplex] infections |
| B02 | Zoster [herpes zoster] |
| B25 | Cytomegaloviral disease |
| B97.7 | Papillomaviruses as the cause of diseases classified to other chapters |
| L29.3 | Unspecified anogenital pruritus |
| N76 | Other inflammatory diseases of vagina and vulva |
| Z29.8 | Other specified prophylactic measures |
| ICD-11 code | Indication |
| 1A94.Z | Anogenital herpes simplex virus infection without further specification |
| 1A95.Z | Anogenital warts, unspecified |
| 1D82.Z | Cytomegaloviral disease, unspecified |
| 1E91.Z | Herpes zoster, unspecified |
| 1F00.Z | Infections due to herpes simplex virus, unspecified |
| EC90.5 | Anogenital pruritus |
| GA00 | Vulvitis |
| GA02.Z | Unspecified vaginitis |
| GA0Z | Inflammatory diseases of female genital tract, unspecified |
| QC05.Z | Prophylactic measures, unspecified |
| XN8JY | Human papillomavirus |
Dosage Regimen
| The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen. |
Apply externally, intravaginally, or intraurethrally as directed.
For human papillomavirus (HPV) infection, including high oncogenic risk types and anogenital warts, apply the spray to the affected area 2-3 times daily for a minimum of 4 weeks.
For herpes simplex virus (HSV) types I and II and for Varicella Zoster (herpes zoster), apply to lesions 3-4 times daily. Continue application for 5-7 days or until symptoms resolve.
For cytomegalovirus (CMV) infection, apply the spray 2 times daily for a duration determined by the physician.
For the prevention of viral infection recurrences (HSV, HPV, CMV, Varicella Zoster), apply once daily for 1-2 weeks during inter-episodic periods.
For the prevention and treatment of cervical pathologies and anogenital warts, use intravaginally. Administer 1-2 spraysonce or twice daily.
For conditions with decreased local immunity (nonspecific vulvovaginitis, candidal vulvovaginitis, bacterial vaginosis), apply 1-2 times daily as part of complex therapy until clinical improvement.
For symptoms of discomfort (itching, burning, dryness) in the genital area, apply to the affected mucosa as needed to relieve symptoms.
The duration of therapy is determined by the severity of the condition and clinical response. Do not discontinue application prematurely. If no improvement is observed, consult a physician.
Adverse Reactions
Local reactions: allergic reactions, including in the form of contact dermatitis.
Contraindications
Hypersensitivity to the active substance.
Use in Pregnancy and Lactation
Approved for use throughout the entire period of pregnancy and the period of breastfeeding.
Use in Hepatic Impairment
The drug is approved for use in hepatic impairment.
Use in Renal Impairment
The drug is approved for use in renal impairment.
Geriatric Use
The drug is approved for use in elderly patients.
Special Precautions
In case of signs of intolerance, application should be discontinued.
Drug Interactions
With simultaneous use of ammonium glycyrrhizinate and other antiviral drugs, in particular derivatives of acyclovir, iodouridine, interferon, and immunomodulators, its action is enhanced.
Storage Conditions
Store at 15°C (59°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.
Dispensing Status
Over-the-Counter
Important Safety Information
This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.
Medical Disclaimer
Actovegin pills 200mg, 50pcs
Fenotropil pills 100mg, 60pcs
Arbidol, capsules 100mg, 40pcs
OKI, sachets 80mg 2g, 12pcs
Cortexin, 10mg, 5ml, 10pcs
Cavinton Comfort, dispersible pills 10mg 90pcs
Belosalic, lotion solution for external use spray 100ml
Ingavirin capsules 90mg, 10pcs 